South Korea Veterinary Monoclonal Antibodies Market (2025-2030)
The South Korea Veterinary Monoclonal Antibodies Market was valued at $17.08 Million in 2025 and projected to reach to $27.54 Million by 2030, representing a compound annual growth rate of 10.0%. South Korea's veterinary monoclonal antibodies market is poised for sustained expansion, driven by the country's sophisticated biotechnology infrastructure and increasing investment in animal health innovation.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
South Korea Veterinary Monoclonal Antibodies Market Trends and Insights
- This 10.0% compound annual growth rate reflects South Korea's advancing animal healthcare infrastructure and increasing adoption of targeted immunotherapies in veterinary medicine.
- South Korea's strong biotechnology sector and rising pet ownership are driving demand for innovative diagnostic and therapeutic monoclonal antibody solutions. The South Korea market benefits from the country's sophisticated veterinary care standards and growing investment in companion animal health.
- South Korea's regulatory environment supports the development and commercialization of advanced veterinary biologics, positioning the nation as a key player in the Asia Pacific region.
- Between 2025 and 2030, South Korea is expected to see accelerated adoption of monoclonal antibody-based treatments across companion animals and livestock applications, supported by increasing veterinary spending and technological advancement..
Key Market Statistics
- CAGR (2025-2030) 10.0% CAGR
- Market Size, 2025 ~USD 17.08 Million
- Forecast, 2030 ~USD 27.54 Million
- Country South Korea
South Korea Veterinary Monoclonal Antibodies Market Overview
Market Valuation Growth :
South Korea's veterinary monoclonal antibodies market is valued at USD 17.08 million in 2025, with projections reaching USD 27.54 million by 2030, representing a robust 10% CAGR over the forecast period.
Biotechnology Leadership :
South Korea's advanced biotechnology sector and strong R&D capabilities position the country as a key hub for developing innovative veterinary immunotherapies and monoclonal antibody applications.
Enhanced Animal Healthcare Infrastructure :
Significant investments in veterinary healthcare facilities and modernized animal treatment centers across South Korea are driving increased adoption of targeted immunotherapies in companion and livestock animals.
Rising Immunotherapy Adoption :
Growing awareness among South Korean veterinarians and pet owners regarding the efficacy of monoclonal antibodies for treating chronic diseases and cancers in animals is accelerating market penetration.
South Korea Veterinary Monoclonal Antibodies Market Dynamics
- The 10% CAGR reflects growing demand for advanced therapeutic solutions in both companion animal and livestock sectors, supported by rising pet ownership rates and enhanced veterinary care standards.
- South Korea's regulatory environment and strong pharmaceutical manufacturing capabilities create favorable conditions for market players.
- The forecast period will likely see increased collaboration between domestic biotech firms and international veterinary pharmaceutical companies, further accelerating market development and therapeutic adoption across the region..
Related Ecosystem
Animal Health
- Polymerase Chain Reaction (PCR) Tests
- Porcine
- Immunodiagnostics
- Lateral Flow Assays
- Microarrays
- Zoetis Inc.
- Patterson Companies, Inc.
- Virbac
- Elanco Animal Health Incorporated
- BOEHRINGER INGELHEIM GMBH
Key Takeaways
- South Korea's veterinary monoclonal antibodies market is valued at USD 17.08 million in 2025, growing at a 10.0% CAGR through 2030.
- South Korea's advanced biotechnology infrastructure and high pet ownership rates are primary drivers of market expansion.
- South Korea is projected to reach USD 27.54 million in market size by 2030, reflecting strong regional demand for immunotherapeutic solutions.
- South Korea's regulatory framework and veterinary care standards position it as a leading market within the Asia Pacific region.
Veterinary Monoclonal Antibodies Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | BEDINVETMAB (LIBRELA) (Product) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 12.4% from 2025 to 2030 |
| Largest Segment | SUBCUTANEOUS ROUTE OF ADMINISTRATION (Route Of Administration) |
| Market Size Base Year (Billions) | ~USD 1.71 (2025) |
| Revenue Forecast (Billions) | ~USD 3.06 (2030) |
| Segments Covered | Animal Type, Product, Route Of Administration, Therapy Area, End User, Animal Type 2023-2030 |
South Korea Veterinary Monoclonal Antibodies Market Report Segmentation
6 segment dimensions are covered across the global market.
By Animal Type
- Canines
- Felines
- Other Animal Types
- Other Animals
By Product
- Bedinvetmab (Librela)
- Canine Parvovirus Monoclonal Antibody (Cpma)
- Frunevetmab (Solensia)
- Gilvetmab
- Lokivetmab (Cytopoint)
- Other Products
By Route Of Administration
- Intravenous (Iv) Route Of Administration
- Intravenous Route Of Administration
- Oral Route Of Administration
- Subcutaneous (Sc) Route Of Administration
- Subcutaneous Route Of Administration
By Therapy Area
- Dermatology
- Infectious Diseases
- Oncology
- Other Therapy Areas
- Pain Management
By End User
- Other End Users
- Veterinary Clinics
- Veterinary Hospitals/ Specialty Centers
- Veterinary Hospitals/Specialty Clinics
- Veterinary Research & Academic Institutes
By Animal Type 2023-2030
- Canines
- Felines
- Other Animals
Target Audience
- Veterinary Pharmaceutical Companies : Manufacturers and distributors of veterinary therapeutics need South Korea-specific market data to develop localized product strategies, pricing models, and distribution partnerships in this growing biotech hub.
- Biotech and Immunotherapy Firms : Companies developing monoclonal antibody technologies require detailed South Korea market insights to identify licensing opportunities, R&D collaborations, and commercialization pathways in the region.
- Investment and Private Equity Firms : Investors evaluating opportunities in South Korea's animal healthcare sector need comprehensive market data to assess growth potential, competitive positioning, and exit opportunities in veterinary therapeutics.
- Veterinary Hospital Networks and Clinics : Large veterinary practice groups and animal healthcare providers need market intelligence to understand emerging treatment options, procurement strategies, and patient demand for monoclonal antibody therapies.
- Government and Regulatory Bodies : South Korean health authorities and agricultural agencies require market analysis to inform policy decisions, reimbursement frameworks, and regulatory standards for veterinary monoclonal antibody products.
Reasons to Buy this Report
- Market-Specific Growth Projections : Access detailed South Korea-specific forecasts showing 10% CAGR growth from USD 17.08M to USD 27.54M by 2030, enabling precise investment and expansion planning in this high-potential market.
- Competitive Landscape Intelligence : Understand South Korea's unique competitive dynamics, local biotech players, and market entry strategies specific to the country's regulatory environment and veterinary healthcare ecosystem.
- Sector-Specific Opportunity Analysis : Identify high-growth segments within South Korea's veterinary monoclonal antibodies market, including companion animal oncology, livestock immunotherapy, and emerging therapeutic applications.
- Strategic Partnership Insights : Discover collaboration opportunities with South Korean biotech firms, veterinary pharmaceutical companies, and research institutions driving innovation in monoclonal antibody development.
- Regulatory and Market Access Guidance : Gain actionable insights into South Korea's veterinary drug approval processes, reimbursement frameworks, and market entry requirements for monoclonal antibody products.
Frequently asked questions
What is the current size of South Korea's veterinary monoclonal antibodies market?
South Korea's veterinary monoclonal antibodies market is valued at USD 17.08 million in 2025.
What is the projected market size for South Korea by 2030?
South Korea's veterinary monoclonal antibodies market is projected to reach USD 27.54 million by 2030.
What is the CAGR for South Korea's veterinary monoclonal antibodies market?
South Korea's veterinary monoclonal antibodies market is expected to grow at a compound annual growth rate of 10.0% from 2025 to 2030.
What factors are driving growth in South Korea's veterinary monoclonal antibodies market?
South Korea's market growth is driven by advanced biotechnology capabilities, rising pet ownership, increasing veterinary spending, and strong regulatory support for innovative animal health solutions.
How does South Korea's market compare to other Asia Pacific countries?
South Korea's sophisticated veterinary care standards, robust biotechnology sector, and high pet ownership position it as a leading market within the Asia Pacific region for veterinary monoclonal antibodies.
RESEARCH METHODOLOGY
This study involved the extensive use of both primary and secondary sources. The research process involved evaluating various factors affecting the industry to identify the segmentation, industry trends, key players, competitive landscape, market dynamics, and growth strategies.
Secondary Research
In the secondary research process, various secondary sources were referred to, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect valuable information for an extensive, technical, market-oriented, and commercial study of the veterinary monoclonal antibodies market. It was also used to obtain information about the key players, market classification & segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various primary sources from the supply and demand sides were interviewed to obtain critical qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, vice presidents, chairpersons, chief executive officers, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary monoclonal antibodies market. Primary sources from the demand side include professionals from veterinary hospitals and clinics, academic & research institutes, and pet owners.
Breakdown of primary interviews
Note: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.
Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the veterinary monoclonal antibodies market was determined after data triangulation from two approaches, as mentioned below. After each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
Veterinary monoclonal antibodies are laboratory-produced antibodies designed to target specific antigens in animals, offering precise treatment for conditions like atopic dermatitis, osteoarthritis, and infectious diseases. These species-specific biologics are engineered to work effectively in the immune systems of dogs, cats, or livestock. They represent a significant advancement over traditional drugs by providing targeted therapy with fewer side effects.
Stakeholders
- Veterinary monoclonal antibody manufacturers
- Animal healthcare product manufacturers
- Veterinary monoclonal antibody distributors and wholesalers
- Animal welfare associations
- Veterinary clinics and care centers
- Research and consulting firms
- Veterinary R&D organizations
- Contract research organizations
- Contract manufacturing organizations
- Venture capitalists
Report Objectives
- To define, describe, and forecast the veterinary monoclonal antibodies market by animal type, product, therapy area, route of administration, end user, and region
- To identify and analyze key drivers, restraints, opportunities, and challenges influencing market growth
- To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI, case study analysis, adjacent market analysis, unmet needs/end user expectations, and trends and disruptions impacting customer business in the market
- To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze opportunities for stakeholders and provide details of the competitive landscape for key players
- To strategically profile key players in this market and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market
Get the Full Veterinary Monoclonal Antibodies Market Report
Full forecast, segment splits, and company analysis for all Veterinary Monoclonal Antibodies Market.
- Canada Veterinary Monoclonal Antibodies Market
- US Veterinary Monoclonal Antibodies Market
- Germany Veterinary Monoclonal Antibodies Market
- France Veterinary Monoclonal Antibodies Market
- UK Veterinary Monoclonal Antibodies Market
- Italy Veterinary Monoclonal Antibodies Market
- Spain Veterinary Monoclonal Antibodies Market
- Netherlands Veterinary Monoclonal Antibodies Market
- Japan Veterinary Monoclonal Antibodies Market
- China Veterinary Monoclonal Antibodies Market
- India Veterinary Monoclonal Antibodies Market
- Australia Veterinary Monoclonal Antibodies Market
- New Zealand Veterinary Monoclonal Antibodies Market
- Brazil Veterinary Monoclonal Antibodies Market
- Mexico Veterinary Monoclonal Antibodies Market
- Rest Of Europe Veterinary Monoclonal Antibodies Market
- Rest Of Asia Pacific Veterinary Monoclonal Antibodies Market
- Rest Of Latin America Veterinary Monoclonal Antibodies Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
